Sight Sciences (SGHT) Gets a Buy from UBS

In a report released yesterday, Danielle Antalffy from UBS reiterated a Buy rating on Sight Sciences, with a price target of $5.00. The company’s shares opened today at $3.35.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Antalffy covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Dexcom. According to TipRanks, Antalffy has an average return of 2.6% and a 51.43% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sight Sciences with a $4.21 average price target, a 25.67% upside from current levels. In a report released on October 1, Lake Street also reiterated a Buy rating on the stock with a $5.00 price target.

SGHT market cap is currently $176M and has a P/E ratio of -3.50.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGHT in relation to earlier this year. Most recently, in July 2025, JEREMY B. HAYDEN, the CLO of SGHT sold 9,160.00 shares for a total of $38,197.20.